ASCO-SITC 2019—Adding nelipepimut-S to trastuzumab boosts DFS in TNBC


  • Melissa Pandika
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adding nelipepimut-S (NPS) to trastuzumab significantly extended disease-free survival (DFS) in a phase 2b study of patients with triple-negative breast cancer (TNBC).

Why this matters

  • No targeted therapies approved for TNBC.
  • Warrants confirmatory phase 3 trial in TNBC.

Study design

  • Final analysis of multicenter, single-blinded phase 2b trial in 275 patients with HER2 low-expressing tumors, randomly assigned to granulocyte macrophage-colony stimulating factor (GM-CSF) with placebo or NPS; all received trastuzumab every 3 weeks for 1 year.
    • GM-CSF or NPS+GM-CSF was given every 3 weeks for 6 cycles, starting with the third trastuzumab dose, and boosters every 6 months x 4.
  • Primary endpoint: DFS at 24 months.
  • Funding: George E. Peoples.

Key results

  • Recurrences
    • Median follow-up: 24.7 months.
    • Intention-to-treat (ITT)-All patients: No significant difference between arms.
    • ITT-TNBC patients:
      • NPS+trastuzumab (n=53): 7.5%.
      • Trastuzumab (n=44): 26.7%.
      • P=.01.
  • DFS
    • ITT-All patients: No significant difference in 24-, 36-month DFS between arms.
    • ITT-TNBC patients:
      • NPS+trastuzumab (n=53)
        • 24 months: 92.6%.
        • 36 months: 82.3%.
      • Trastuzumab (n=44)
        • 24 months: 70.2%.
        • 36 months: 70.2%.
      • P=.013, HR 0.26.
  • NPS+trastuzumab safe; no notable differences between arms.

Limitations

  • Unclear if TNBC subgroup analysis planned/post-hoc.
  • Data on memory attributes of NPS-induced T-cells could help clarify whether secondary prevention provided.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit